Drug Type Small molecule drug |
Synonyms Temuterkib Mesylate, LY 3214996, LY3214996 |
Target |
Action inhibitors |
Mechanism ERK inhibitors(ERK subfamily inhibitors), ERK1 inhibitors(Extracellular-signal-regulated kinase1 inhibitors), ERK2 inhibitors(Extracellular-signal-regulated kinase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H27N7O2S |
InChIKeyJNPRPMBJODOFEC-UHFFFAOYSA-N |
CAS Registry1951483-29-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | United States | 27 May 2020 | |
Metastatic Pancreatic Cancer | Phase 2 | United States | 27 May 2020 | |
Acute Myeloid Leukemia | Phase 1 | United States | 15 Jul 2020 | |
Glioblastoma Multiforme | Phase 1 | United States | 11 Jul 2020 | |
Recurrent Glioblastoma | Phase 1 | United States | 11 Jul 2020 | |
CD19 Expressing Malignancies | Phase 1 | - | 03 Feb 2020 | |
Chronic Lymphocytic Leukemia | Phase 1 | - | 03 Feb 2020 | |
Mantle-Cell Lymphoma | Phase 1 | - | 03 Feb 2020 | |
Marginal Zone B-Cell Lymphoma | Phase 1 | - | 03 Feb 2020 | |
Waldenstrom Macroglobulinemia | Phase 1 | - | 03 Feb 2020 |
Phase 2 | 52 | (LY3214996 and HCQ Combination) | wsugiungne = vhbymuyyyi mhpdfdbbfe (nbqpvibbxj, tgunyxjshy - dzlevtoqvg) View more | - | 27 Nov 2024 | ||
(LY3214996-Monotherapy) | wsugiungne = fhhfinhftn mhpdfdbbfe (nbqpvibbxj, fkjcsoycwb - erbtodsjng) View more | ||||||
Phase 2 | 16 | zxdkakwkog = kdiqmchgfa qufxscrreo (strclozanl, uxwbntycdl - blallptzkz) View more | - | 07 Aug 2024 | |||
NCT04534283 (ASCO2023) Manual | Phase 2 | 12 | huvgxaqxnb(jgvjodskic) = agyffxjgzs vvdwivokdb (kgfehcspiv ) View more | Positive | 31 May 2023 | ||
Early Phase 1 | - | ddxgnzyzpn(hnhxgtzdwd) = czocugqxay dglhvyngsr (zxmtrrwfxs ) | - | 12 Nov 2021 | |||
ddxgnzyzpn(hnhxgtzdwd) = koxagqphhc dglhvyngsr (zxmtrrwfxs ) | |||||||
Phase 1 | 51 | nickokfebf(zojmvqqbdx) = grade (G) 3 cough and fatigue, G3 dehydration, increased creatinine (Cr), G3 increased CPK, G3 rash > 7 days, and 1 pt with renal failure. qcweihhtyg (ddabhwdkyq ) View more | Positive | 03 Jun 2019 | |||
Phase 1 | - | 210 | xwuzivnpkb(awjfduwegq) = ynakgtmnqo deaytrflpt (jjufmslatd ) | - | 01 Jul 2017 | ||
Phase 1 | 210 | rzijylsnqu(sbxiltnwdd) = rdtrupmosy dyjovvwmwk (bezpuwfpte ) | Positive | 01 Jul 2017 |